Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
NASDAQ:CDXS
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.32Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 0.00%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
Despite challenges such as a significant year-over-year revenue decline and increased net loss, Codexis maintains a strong financial position and projects future growth driven by advancements in its ecosynthesis platform and machine learning capabilities. The sentiment remains cautiously positive due to strategic progress in key areas.Company Guidance
During the Codexis First Quarter 2025 Earnings Conference Call, management reiterated their 2025 revenue guidance and shared various metrics underscoring their confidence in meeting these targets. The Q1 revenue was $7.5 million, with a product gross margin of 55%, up from 49% in Q1 2024. Despite the revenue drop from $17.1 million in Q1 2024, the company emphasized that revenue is expected to ramp up in the second half of 2025, largely driven by their ecosynthesis platform and increasing orders for their double-stranded RNA ligase from large pharma customers. The company maintains a strong cash position with $59.8 million in cash and investments, supporting operations through to their projected cash flow positivity by the end of 2026. Management highlighted that their ecosynthesis technology could reduce costs by 70% and enable five times larger batch sizes compared to traditional methods, which is crucial as more siRNA pipeline assets advance through clinical trials.Strong Financial Position
Codexis maintained a strong cash position, with $59.8 million in cash, cash equivalents, and investments, expected to fund operations until cash flow positivity by the end of 2026.
Pharma Biocatalysis Revenue Growth
Despite a delay in a $2.5 million payment, Codexis is confident in revenue growth for 2025, driven by new customers and commercial milestones in the Pharma Biocatalysis sector.
Ecosynthesis Platform Progress
Codexis has made significant progress with its ecosynthesis platform, signing its first revenue-generating ECO Contract and showcasing technical advancements at the TIDES meeting.
Improved Product Gross Margin
Product gross margin improved to 55% in Q1 2025, up from 49% in Q1 2024, driven by a shift to more profitable products.
Machine Learning Integration
Codexis successfully launched a machine learning tool for optimized enzyme selection, reducing process development time and cost for customers.
---
CDXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CDXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $2.47 | ― | ― |
Feb 27, 2025 | $3.93 | $3.04 | -22.65% |
Oct 31, 2024 | $3.14 | $3.50 | +11.46% |
Aug 08, 2024 | $3.15 | $2.80 | -11.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Codexis (CDXS) report earnings?
Codexis (CDXS) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Codexis (CDXS) earnings time?
Codexis (CDXS) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CDXS EPS forecast?
CDXS EPS forecast for the fiscal quarter 2025 (Q2) is -0.19.
---